bacil pharma has approved a proposal to raise funds by way of a rights issue of equity shares for an aggregate amount of up to ₹50 Cr. The decision was taken during a board meeting held on July 9, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company intends to utilise the capital to bolster its financial resources, subject to statutory and regulatory approvals.

The board approved increasing the authorised share capital by ₹45 Cr through the addition of 4,50,00,000 equity shares of ₹10 each. Following this increase, the total authorised capital will stand at ₹65 Cr. This move requires the consequent alteration of the capital clause of the Memorandum of Association and is subject to shareholder approval in the upcoming general meeting.

To facilitate the rights issue, the board appointed M/s Purva Sharegistry (India) Private Limited as the registrar and Axis Bank Limited as the banker to the issue. Acuite Ratings & Research Limited was appointed as the monitoring agency in accordance with SEBI ICDR Regulations. A rights issue committee was formed, comprising Chaitali Kalpataru Shah as Chairman and Vivek Mukesh Yadav and Omprakash Pyarelal Sonar as members.

The board accepted the resignations of Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya as independent directors, effective July 9, 2026. Both directors cited pre-occupation in other assignments and an inability to devote sufficient time to the company's affairs as reasons for their departure. The trading window for dealing in the company's securities will remain closed for all designated persons and their immediate relatives until 48 hours after the declaration of the board meeting outcome.

Bacil Pharma has approved a proposal to raise funds by way of a rights issue of equity shares for an aggregate amount of up to ₹50,00,00,000. The decision was taken during a board meeting held on July 9, 2026, aimed at bolstering the company's capital base. The rights issue will be conducted in accordance with the Companies Act, 2013, and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, subject to necessary approvals.

To facilitate the issuance, the board approved an increase in the authorised share capital by ₹45,00,00,000, divided into 4,50,00,000 equity shares of ₹10 each. This will raise the total authorised share capital to ₹65,00,00,000 and necessitate the alteration of the capital clause of the Memorandum of Association, pending shareholder approval.

Rights Issue Committee and Appointments

The board constituted a Rights Issue Committee to oversee the process. The committee includes Chaitali Kalpataru Shah as Chairman, and Vivek Mukesh Yadav and Omprakash Pyarelal Sonar as members. Additionally, the board appointed M/s Purva Sharegistry (India) Private Limited as the Registrar, Axis Bank Limited as the Banker to the Issue, and Acuite Ratings & Research Limited as the Monitoring Agency.

Board Decisions

The meeting also saw the approval of resignations from Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, both Independent Directors. Ms. Chaitali Kalpataru Shah and the Company Secretary were authorized to complete necessary filings and documentation for the rights issue.